Publication: 3226

Depth of response to daratumumab (DARA), lenalidomide, bortezomib, and dexamethasone (RVD) improves over time in patients (pts) with transplant-eligible newly diagnosed multiple myeloma (NDMM): GRIFFEN study update (AFT-29)

Citation:: Blood vol 134 (Supplement_1) 691

Meeting Instance:: ASH 2019
Year:: 2019
Type:: Abstract
Sub type:: Oral
Funding:: AFT
Endpoint:: Secondary
Analysis:: Primary
Data Sharing:: No-Data-Sharing
Status:: Presented/Published
Citation Status:: epub

Note:

Methodological:: No
Biospecimen:: No
SDC:: No

Parents:: None
Children:: 3304

Program:: OGC
Primary Committee:: Myeloma
Sec. Committees:

Pharmas:: Jansen
Grants:

Corr. Author:
Authors:: Peter M. Voorhees Jonathan L. Kaufman Jacob Laubach Douglas W. Sborov Brandi Reeves Cesar Rodriguez Ajai Chari Rebecca Silbermann Luciano J. Costa Larry D. Anderson Jr Nitya Nathwani Nina Shah Yvonne A. Efebera Caitlin Costello Andrzej Jakubowiak Tanya M. Wildes Robert Z. Orlowski Kenneth H. Shain Andrew J. Cowan Sean Murphy Yana Lutska Huiling Pei Jon Ukropec Jessica Vermeulen Carla de Boer Daniela Hoehn Thomas S. Lin Paul G. Richardson

Networks:

Study: AFT-29 (GRIFFIN)
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:: 2

Keywords: